Larimar Therapeutics (LRMR) Stock Forecast & Price Target

Compare

643 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

LRMR Analyst Ratings

Strong Buy

10 Buy

0 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Larimar

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

LRMR Stock 12 Month Forecast

Average Price Target

$20.43

▲(662.31%Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Larimar Therapeutics in the last 3 months. The average price target is $20.43 with a high forecast of $40.00 and a low forecast of $10.00. The average price target represents a 662.31% change from the last price of $2.68.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","11":"$11","21":"$21","31":"$31","41":"$41"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$20.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,11,21,31,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.86,5.716923076923077,8.573846153846153,11.43076923076923,14.287692307692307,17.144615384615385,20.00153846153846,22.858461538461537,25.715384615384615,28.572307692307692,31.42923076923077,34.286153846153844,37.14307692307692,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.86,4.211538461538462,5.563076923076923,6.914615384615384,8.266153846153847,9.617692307692307,10.96923076923077,12.32076923076923,13.672307692307692,15.023846153846154,16.375384615384615,17.72692307692308,19.07846153846154,{"y":20.43,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.86,3.4092307692307693,3.9584615384615383,4.507692307692308,5.056923076923077,5.6061538461538465,6.155384615384616,6.704615384615385,7.253846153846155,7.803076923076924,8.352307692307694,8.901538461538463,9.45076923076923,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.46,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.35,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.24,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.32,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.91,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.27,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.74,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.2,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.87,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.84,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.03,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.86,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$40.00

Average Price Target$20.43

Lowest Price Target$10.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Samantha SemenkowCiti

Citi

―

Buy

―

Reiterated

05/05/25

Larimar Therapeutics (LRMR) Gets a Buy from Citi

Joon LeeTruist Financial

Truist Financial

―

Buy

―

Reiterated

05/01/25

Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (NYSE: BHC), Humana (NYSE: HUM) and Larimar Therapeutics (NASDAQ: LRMR)

Joseph SchwartzLeerink Partners

Leerink Partners

$25

Buy

832.84%

Upside

Reiterated

04/30/25

Analysts Offer Insights on Healthcare Companies: BioNTech SE (NASDAQ: BNTX), PTC Therapeutics (NASDAQ: PTCT) and Larimar Therapeutics (NASDAQ: LRMR)

Myles MinterWilliam Blair

William Blair

―

Buy

―

Reiterated

04/30/25

Optimistic Buy Rating for Larimar Therapeutics Amid Promising Phase II Study and Regulatory Progress

Cory Jubinville, PhDLifeSci Capital

LifeSci Capital

$40

Buy

1392.54%

Upside

Reiterated

04/30/25

Buy Rating for Larimar Therapeutics Driven by Regulatory Progress and FDA Support

Jonathan WollebenCitizens JMP

Citizens JMP

$21

Buy

683.58%

Upside

Reiterated

04/23/25

Citizens JMP reiterates Market Outperform Rating on Larimar Therapeutics (LRMR)Citizens JMP analyst Jonathan Wolleben reiterated a Market Outperform rating and $21.00 price target on Larimar Therapeutics (NASDAQ: LRMR).

Joel BeattyRobert W. Baird

Robert W. Baird

$13→$10

Buy

273.13%

Upside

Reiterated

03/25/25

Larimar Therapeutics price target lowered to $10 from $13 at BairdLarimar Therapeutics price target lowered to $10 from $13 at Baird

Catherine NovackJonesTrading

JonesTrading

$14

Buy

422.39%

Upside

Reiterated

03/25/25

Jones Trading reiterates Buy Rating on Larimar Therapeutics (LRMR), PT $14Jones Trading analyst Catherine Novack reiterated a Buy rating and $14.00 price target on Larimar Therapeutics (NASDAQ: LRMR)

Edward WhiteH.C. Wainwright

H.C. Wainwright

$15→$16

Buy

497.01%

Upside

Reiterated

03/25/25

Promising Outlook for Larimar Therapeutics: Buy Rating on Nomlabofusp's Potential in Treating Friedreich's Ataxia

Laura ChicoWedbush

Wedbush

$22→$17

Buy

534.33%

Upside

Reiterated

03/24/25

Larimar Therapeutics (LRMR) PT Lowered to $17 at WedbushWedbush analyst Laura Chico lowered the price target on Larimar Therapeutics (NASDAQ: LRMR) to $17.00 (from $22.00) while maintaining a Outperform rating.

Andreas ArgyridesOppenheimer

Oppenheimer

$26

Buy

870.15%

Upside

Reiterated

12/17/24

Oppenheimer Reaffirms Their Buy Rating on Larimar Therapeutics (LRMR)

Yatin SunejaGuggenheim

Guggenheim

$26

Buy

870.15%

Upside

Reiterated

12/16/24

Guggenheim reiterates Buy Rating on Larimar Therapeutics (LRMR)Guggenheim analyst Yatin Suneja reiterated a Buy rating and $26.00 price target on Larimar Therapeutics (NASDAQ: LRMR).

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Samantha SemenkowCiti

Citi

―

Buy

―

Reiterated

05/05/25

Larimar Therapeutics (LRMR) Gets a Buy from Citi

Joon LeeTruist Financial

Truist Financial

―

Buy

―

Reiterated

05/01/25

Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (NYSE: BHC), Humana (NYSE: HUM) and Larimar Therapeutics (NASDAQ: LRMR)

Joseph SchwartzLeerink Partners

Leerink Partners

$25

Buy

832.84%

Upside

Reiterated

04/30/25

Analysts Offer Insights on Healthcare Companies: BioNTech SE (NASDAQ: BNTX), PTC Therapeutics (NASDAQ: PTCT) and Larimar Therapeutics (NASDAQ: LRMR)

Myles MinterWilliam Blair

William Blair

―

Buy

―

Reiterated

04/30/25

Optimistic Buy Rating for Larimar Therapeutics Amid Promising Phase II Study and Regulatory Progress

Cory Jubinville, PhDLifeSci Capital

LifeSci Capital

$40

Buy

1392.54%

Upside

Reiterated

04/30/25

Buy Rating for Larimar Therapeutics Driven by Regulatory Progress and FDA Support

Jonathan WollebenCitizens JMP

Citizens JMP

$21

Buy

683.58%

Upside

Reiterated

04/23/25

Joel BeattyRobert W. Baird

Robert W. Baird

$13→$10

Buy

273.13%

Upside

Reiterated

03/25/25

Larimar Therapeutics price target lowered to $10 from $13 at BairdLarimar Therapeutics price target lowered to $10 from $13 at Baird

Catherine NovackJonesTrading

JonesTrading

$14

Buy

422.39%

Upside

Reiterated

03/25/25

Jones Trading reiterates Buy Rating on Larimar Therapeutics (LRMR), PT $14Jones Trading analyst Catherine Novack reiterated a Buy rating and $14.00 price target on Larimar Therapeutics (NASDAQ: LRMR)

Edward WhiteH.C. Wainwright

H.C. Wainwright

$15→$16

Buy

497.01%

Upside

Reiterated

03/25/25

Promising Outlook for Larimar Therapeutics: Buy Rating on Nomlabofusp's Potential in Treating Friedreich's Ataxia

Laura ChicoWedbush

Wedbush

$22→$17

Buy

534.33%

Upside

Reiterated

03/24/25

Andreas ArgyridesOppenheimer

Oppenheimer

$26

Buy

870.15%

Upside

Reiterated

12/17/24

Oppenheimer Reaffirms Their Buy Rating on Larimar Therapeutics (LRMR)

Yatin SunejaGuggenheim

Guggenheim

$26

Buy

870.15%

Upside

Reiterated

12/16/24

Guggenheim reiterates Buy Rating on Larimar Therapeutics (LRMR)Guggenheim analyst Yatin Suneja reiterated a Buy rating and $26.00 price target on Larimar Therapeutics (NASDAQ: LRMR).

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Larimar Therapeutics

1 Month

xxx

Success Rate

14/26 ratings generated profit

Average Return

+4.75%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 53.85% of your transactions generating a profit, with an average return of +4.75% per trade.

3 Months

xxx

Success Rate

14/26 ratings generated profit

Average Return

+17.53%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 53.85% of your transactions generating a profit, with an average return of +17.53% per trade.

1 Year

Jonathan WollebenCitizens JMP

Success Rate

14/26 ratings generated profit

Average Return

+17.47%

reiterated a buy rating 2 months ago

Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of +17.47% per trade.

2 Years

xxx

Success Rate

10/26 ratings generated profit

Average Return

+19.75%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 38.46% of your transactions generating a profit, with an average return of +19.75% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LRMR Analyst Recommendation Trends

Rating

Jan 25

Feb 25

Mar 25

Apr 25

May 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, LRMR has received 16 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. LRMR average Analyst price target in the past 3 months is 20.43.

Each month's total comprises the sum of three months' worth of ratings.

LRMR Financial Forecast

LRMR Earnings Forecast

Next quarter’s earnings estimate for LRMR is -$0.48 with a range of -$0.52 to -$0.39. The previous quarter’s EPS was -$0.46. LRMR beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 44.19% of the time in the same period. In the last calendar year LRMR has Outperformed its overall industry.

No data currently available

LRMR Sales Forecast

Next quarter’s sales forecast for LRMR is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. LRMR beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 56.25% of the time in the same period. In the last calendar year LRMR has Preformed in-line its overall industry.

LRMR Stock Forecast FAQ

What is LRMR’s average 12-month price target, according to analysts?

Based on analyst ratings, Larimar Therapeutics, Inc.’s 12-month average price target is 20.43.

What is LRMR’s upside potential, based on the analysts’ average price target?

Larimar Therapeutics, Inc. has 662.31% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is LRMR a Buy, Sell or Hold?

Larimar Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.

What is Larimar Therapeutics, Inc.’s price target?

The average price target for Larimar Therapeutics, Inc. is 20.43. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $40.00 ,the lowest forecast is $10.00. The average price target represents 662.31% Increase from the current price of $2.68.

What do analysts say about Larimar Therapeutics, Inc.?

Larimar Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of LRMR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Larimar Therapeutics (LRMR) Stock Forecast & Price Target

LRMR Analyst Ratings

LRMR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Larimar Therapeutics

LRMR Analyst Recommendation Trends

LRMR Financial Forecast

LRMR Earnings Forecast

LRMR Sales Forecast

LRMR Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts